Recursion Pharmaceuticals reports fourth-quarter and full-year 2025 results Wednesday before the market opens, with investors scrutinizing whether the AI-driven biotech can translate its massive data ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

You aren’t just one thing, and neither is your watch history. Maybe 2025 was your custom keyboard era, or when you became KATSEYE’s biggest fan, or watched a ton of Labubu blind box reveals. More ...

Alphabet and Disney on Friday announced that they've reached a deal to restore content from ABC and ESPN onto Google's YouTube TV. The deal comes after a two-week standoff that resulted in channels ...

YouTube is updating its policies to age-restrict more content containing video game scenes with "graphic violence," the company announced on Tuesday. Starting November 17, the updates will prevent ...

Google experienced outages in multiple countries on Thursday morning, with core services such as Gmail and YouTube experiencing issues, according to the tracking website Downdetector. Eastern and ...

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

The world’s largest video platform has told content moderators to favor “freedom of expression” over the risk of harm in deciding what to take down. By Nico Grant and Tripp Mickle Reporting from San ...

AI drug discovery specialist Recursion Pharmaceuticals is shelving three of its most advanced drug prospects in an effort to cut costs following a merger last year. Alongside its latest quarterly ...

Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion. The ...

Najat Khan, PhD, Recursion Pharmaceuticals chief R&D officer and chief commercial officer With at least seven of its programs expected to begin human trials or read out clinical data during 2025, ...